Business Propanc Biopharma’s Lead Asset PRP Shows >85% Tumor Growth Inhibition in Preclinical Pancreatic Models Last updated: March 3, 2026 8:48 am By Weekly Voice editorial staff Share 0 Min Read SHARE Preclinical data shines: >85% tumor growth inhibition in pancreatic models, reduced fibrosis and resistance markers, and a gentler safety profile - Advertisement - Share This Article Email Copy Link Print Latest Viral Death Rumours About Netanyahu Debunked as Online Misinformation Spreads NEWS World Explosive Claims Surface Around Iran’s New Supreme Leader as Trump Reacts to Intelligence Briefing NEWS World Global War Escalates: Iran Threatens Hormuz Access as Trump Pressures Allies NEWS World Company Fined $100,000 After Providing False Records to an Officer Ontario Unidentified Human Remains, Image Released Crime Inquest into the Death of Justin Fiddler Announced Ontario
